Why blood type O might lower risk for SARS-CoV-2 infection

NewsGuard 100/100 Score

Infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes COVID-19 disease leads to no symptoms in some people and severe and fatal consequences in many others. The development of a disease depends on many factors. For coronaviruses, this includes the different types of physical and chemical bonds formed between the virus and host cells.

In the previous SARS-CoV infection, researchers found that O-glycosylation, or the attachment of carbohydrates to the oxygen group in proteins, played a key role in disease development. For SARS-CoV-2, researchers predict something similar may happen, with the O-glycoproteome being a critical component of the infection.

Although the human angiotensin-converting receptor 2 (ACE2) appears to be the primary receptor of the virus in host cells, the virus likely binds via the formation of an intermediate O-glycan, dominated by the amino acid serine of the virus. In humans, the resulting intermediate structure, which is independent of the blood group, may be replaced by carbohydrates specific to the ABO(H) blood groups.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Blood groups and immunological response

In a new study published as a preprint*, Peter Arend of Philipps University Marburg in Germany proposes a theory of how the SARS-CoV-2 infection occurs via the binding of carbohydrate specifics to blood groups.

After the virus attaches to human cells via the ACE2 protein, studies have suggested that during the host-virus fusion process, the amino acid serine of the virus is critical. Given what is known about serine from previous studies, is it highly probable that binding to the host cells occurs via O-glycosylation.

Disease symptoms seem to occur more in patients with non-O blood groups, suggesting that viral serine targets the saccharides of blood groups A, B, and AB in the glycosylation process. Thus, the innate immune system and its connection to the ABO(H) blood groups may play a key role in the SARS-CoV-2 infection.

In contrast to B-cell activity, which is environmentally induced, the production of non-immune antibody IgM is not restricted to B cells. It can occur spontaneously in murine and human epithelial cells. Previous studies have linked IgM to A-like/Tn antigen, a saccharide of GalNAc linked to serine or threonine.

The viral SARS-CoV-2 serine residues, mobilized by host’s TMPRSS2, highjack the host’s GalNAc metabolism and both blood group O(H) and blood group A are identically infected via blood group independent, trans-species intermediate O-GalNAc-Ser (Tn) glycosylation.
The viral SARS-CoV-2 serine residues, mobilized by host’s TMPRSS2, highjack the host’s GalNAc metabolism and both blood group O(H) and blood group A are identically infected via blood group independent, trans-species intermediate O-GalNAc-Ser (Tn) glycosylation.

IgM undergoes ABO(H) phenotype formation and occurs on cell surfaces and plasma proteins. Serine alone seems to affect the reactivity of this antibody, binding the various epitopes. "Thus, serine residues might also serve as acceptors in phenotypical accommodation of autoreactive antibody activities," writes the author.

This hypothetical process could occur in the blood-group active soluble plasma protein, such as the α2-macroglobulin molecule, whose blood group activity is strictly related to the type of blood group of the person.

This molecule is structurally related to IgM and is involved in the down-regulation of anti-A and anti-B activity in blood groups A and B, respectively. Blood group O maintains the highly anti-glycan anti-A and anti-B activities and loses anti-H.

Anti-A levels in blood group B and anti-B levels in blood group A are lower than in blood group O. Environmentally induced anti-A and anti-B antibodies are only produced in blood group O. Furthermore, IgG, the secondary antibody to anti-A and anti-B seem to be restricted only to this blood group.

SARS-CoV-2 infection related to blood groups

The author writes SARS-CoV-2 possibly escapes the human immune system by hybridization of the ABO(H) blood groups or by mimicking the glycosylation metabolic pathways.

In all the blood groups, the infection occurs by an A-like/Tn intermediate binding. In blood group O, this is replaced by mucin-type fucosylation, synthesizing a hybrid H-type antigen. Thus, in the blood groups A, B, and AB, it is possible that the intermediate A-like/Tn binding is replaced by A-and/or B-allelic mucin-type formation and anti-A-isoagglutinin or anti-B levels are reduced.

In blood group O, there is the least contact with the virus, being bound to the virus only by the formation of the H-type antigen. It is the most protected group when it loses only the anti-H isoagglutinin but retains secondary IgG responses.

In blood group A, anti-A and anti-H formations are blocked, anti-B levels are low, and IgG is not produced. In blood group B, anti-B and anti-H are blocked, anti-A is low, and IgG is not produced. Blood group AB is least protected from the pathogen and has the strongest contact with the virus.

Thus, the lack of anti-A and anti-B antibodies in the A, B, and AB blood groups, protects the cells from self-reactivity against complementary structures, cannot prevent the formation of hybrid structures in later steps of the infection process.

It is likely that in SARS-CoV-2 infection, the autoimmune processes, particularly in non-O blood groups, may contribute to severe symptoms. "However, the individual risk of becoming infected with SARS-CoV-2 or becoming seriously ill cannot be predicted based on a person's ABO(H) blood group affiliation alone because many other risks exist," writes the author.

This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources

Journal references:
  • Preliminary scientific report. Arend, P. (2020) Why Blood Group A Individuals Are at Risk Whereas Blood Group O Individuals Might Be Protected from SARS-CoV-2 (COVID-19) Infection: A Hypothesis Regarding How the Virus Invades the Human Body via ABO(H) Blood Group-Determining Carbohydrates. Preprints. doi:10.20944/preprints202005.0097.v2, https://www.preprints.org/manuscript/202005.0097/v2
  • Peer reviewed and published scientific report. Arend, Peter. 2020. “Why Blood Group a Individuals Are at Risk Whereas Blood Group O Individuals Are Protected from SARS-CoV-2 (COVID-19) Infection: A Hypothesis Regarding How the Virus Invades the Human Body via ABO(H) Blood Group-Determining Carbohydrates.” Immunobiology, November, 152027. https://doi.org/10.1016/j.imbio.2020.152027https://www.sciencedirect.com/science/article/pii/S0171298520305490.

Article Revisions

  • Mar 28 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Lakshmi Supriya

Written by

Lakshmi Supriya

Lakshmi Supriya got her BSc in Industrial Chemistry from IIT Kharagpur (India) and a Ph.D. in Polymer Science and Engineering from Virginia Tech (USA).

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Supriya, Lakshmi. (2023, March 28). Why blood type O might lower risk for SARS-CoV-2 infection. News-Medical. Retrieved on April 28, 2024 from https://www.news-medical.net/news/20201012/Why-blood-type-O-might-lower-risk-for-SARS-CoV-2-infection.aspx.

  • MLA

    Supriya, Lakshmi. "Why blood type O might lower risk for SARS-CoV-2 infection". News-Medical. 28 April 2024. <https://www.news-medical.net/news/20201012/Why-blood-type-O-might-lower-risk-for-SARS-CoV-2-infection.aspx>.

  • Chicago

    Supriya, Lakshmi. "Why blood type O might lower risk for SARS-CoV-2 infection". News-Medical. https://www.news-medical.net/news/20201012/Why-blood-type-O-might-lower-risk-for-SARS-CoV-2-infection.aspx. (accessed April 28, 2024).

  • Harvard

    Supriya, Lakshmi. 2023. Why blood type O might lower risk for SARS-CoV-2 infection. News-Medical, viewed 28 April 2024, https://www.news-medical.net/news/20201012/Why-blood-type-O-might-lower-risk-for-SARS-CoV-2-infection.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Spicing up diabetes management: Mediterranean diet's aromatic herbs lower blood sugar